Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01653028 · ClinicalTrials.gov registry record · Phase 2
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
A Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Myxofibrosarcoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 20
- Study locations
NCT01653028 is a Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Myxofibrosarcoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 72 participants, below the 82-participant average among 11 other Recurrent Adult Soft Tissue Sarcoma trials with a reported enrollment target (12% lower). The trial reports 20 study locations across 2 states.
The verdict
NCT01653028, a Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Myxofibrosarcoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies how well alisertib works in treating patients with sarcoma that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or has spread to other places in the body (metastatic). Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Alisertib
Study Locations (20)
Colorado
- The Medical Center of Aurora - Aurora
- Boulder Community Hospital - Boulder
- Rocky Mountain Cancer Centers-Boulder - Boulder
- Penrose-Saint Francis Healthcare - Colorado Springs
- Rocky Mountain Cancer Centers-Penrose - Colorado Springs
- Porter Adventist Hospital - Denver
- Colorado Blood Cancer Institute - Denver
- Presbyterian - Saint Lukes Medical Center - Health One - Denver
- Rocky Mountain Cancer Centers-Midtown - Denver
- SCL Health Saint Joseph Hospital - Denver
- Rocky Mountain Cancer Centers-Rose - Denver
- Rose Medical Center - Denver
- Colorado Cancer Research Program NCORP - Denver
- Mercy Medical Center - Durango
- Comprehensive Cancer Care and Research Institute of Colorado LLC - Englewood
- Swedish Medical Center - Englewood
- Poudre Valley Hospital - Fort Collins
- Mountain Blue Cancer Care Center - Golden
- North Colorado Medical Center - Greeley
Arizona
- Mayo Clinic in Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2012-08-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01653028
The ClinicalTrials.gov registry entry for NCT01653028 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 82-participant average among 11 other Recurrent Adult Soft Tissue Sarcoma trials with a reported enrollment target (12% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Recurrent Adult Soft Tissue Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01653028 reports 20 study locations spanning 2 distinct geographic areas - top geographies include Colorado, Arizona.
Frequently Asked Questions
What is clinical trial NCT01653028 about?
NCT01653028 is a clinical study titled "Alisertib in Treating Patients With Advanced or Metastatic Sarcoma". This phase II trial studies how well alisertib works in treating patients with sarcoma that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or has spread to other places in the body (metastatic). Alisertib may stop the growth of tumor cells ...
What is the current status of trial NCT01653028?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2012-08-22.
What conditions does trial NCT01653028 study?
This clinical trial studies the following conditions: Recurrent Adult Soft Tissue Sarcoma, Myxofibrosarcoma, Recurrent Liposarcoma, Recurrent Undifferentiated Pleomorphic Sarcoma, Recurrent Malignant Peripheral Nerve Sheath Tumor.
What interventions are being tested in trial NCT01653028?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Alisertib (DRUG).
Who is sponsoring clinical trial NCT01653028?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01653028 being conducted?
This trial has 20 study locations across Arizona, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Adult Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma
COMPLETED · Phase 2
-
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
COMPLETED · Phase 2
-
Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
COMPLETED · Phase 2
-
CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor
COMPLETED · Phase 2
-
A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.